Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：8
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [41] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Jakubowiak, Andrzej J.
    Dytfeld, Dominik
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Nordgren, Brian
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    BLOOD, 2012, 120 (09) : 1801 - 1809
  • [42] A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Feng, Lei
    Oriabure, Onyeka
    Graham, Vivian
    Chen, Wendy
    Badillo, Maria
    Lu, Rebecca
    Lee, Hun J.
    Jain, Preetesh
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    Wang, Michael L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : E243 - E246
  • [43] A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
    R Hájek
    T Masszi
    M T Petrucci
    A Palumbo
    L Rosiñol
    A Nagler
    K L Yong
    A Oriol
    J Minarik
    L Pour
    M A Dimopoulos
    V Maisnar
    D Rossi
    H Kasparu
    J Van Droogenbroeck
    D B Yehuda
    I Hardan
    M Jenner
    M Calbecka
    M Dávid
    J de la Rubia
    J Drach
    Z Gasztonyi
    S Górnik
    X Leleu
    M Munder
    M Offidani
    N Zojer
    K Rajangam
    Y-L Chang
    J F San-Miguel
    H Ludwig
    Leukemia, 2017, 31 : 107 - 114
  • [44] A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Lendvai, Nikoletta
    Hilden, Patrick
    Devlin, Sean
    Landau, Heather
    Hassoun, Hani
    Lesokhin, Alexander M.
    Tsakos, Ioanna
    Redling, Kaitlyn
    Koehne, Guenther
    Chung, David J.
    Schaffer, Wendy L.
    Giralt, Sergio A.
    BLOOD, 2014, 124 (06) : 899 - 906
  • [45] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [46] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark A.
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille N.
    DiPersio, John F.
    Tomasson, Michael H.
    Wildes, Tanya M.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    BLOOD, 2016, 128 (22)
  • [47] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [48] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Tobinai, Kensei
    Taniwaki, Masafumi
    Shumiya, Yoshihisa
    Nakamura, Toru
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (05) : 596 - 604
  • [50] Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Kensei Tobinai
    Masafumi Taniwaki
    Yoshihisa Shumiya
    Toru Nakamura
    Takaaki Chou
    International Journal of Hematology, 2016, 104 : 596 - 604
12345